PTC Therapeutics, Inc. (PTCT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

PTC Therapeutics, Inc. (PTCT) closed at USD 59.67 on 2026-10-14, a change of -11.6 % over the past year, with a market capitalization of USD 5.09B.

PTC Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

PTC Therapeutics, Inc. key figures

Previous close

USD 59.67 (2026-10-14)

1-year change

-11.6 %

Market cap

USD 5.09B

Enterprise value

USD 5.88B

P/E ratio (trailing)

-98.37

P/E ratio (forward)

25.73

EPS (trailing)

-0.62

EPS (forward)

2.37

PEG ratio

n/a

Price to book

-30.73

Revenue growth

101.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.61

Employees

991

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for PTC Therapeutics, Inc. and compare it with other stocks.